Aelis Farma receives the positive opinion of the DSMB for the continuation without change to the protocol of its phase 2b clinical study with AEF0117 in cannabis addiction
The excellent safety and tolerance profile of the compound allows the study to be continued with confidence, the first results of which are expected in mid-2024.
Pier Vincenzo Piazza, Managing Director of Aelis Farma, says: “First of all, we would like to thank all the study participants and the teams of investigators who are helping to advance the understanding of AEF0117 in such a critical area. than cannabis addiction. This positive recommendation from the DSMB confirms the very good safety and tolerance profile of our drug candidate, already observed during its previous evaluation phases, recently published in Nature Medicine. The fact that it is safe and well tolerated in patients in real-life conditions is crucial and very favorable for the further development of AEF0117, the only molecule that to date represents real hope for many people suffering from the pathologies generated by the excessive use of cannabis. »
To receive all of AELIS FARMA’s financial information in real time, send a request by e-mail to [email protected]. Your registration will be immediate.